Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 161 results for prostate cancer

  1. In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal mapping biopsy compared with transperineal non-mapping biopsy in the diagnosis of clinically significant prostate cancer?

    next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal...

    Research recommendation
    Published
    25 October 2019

  2. Reviewing the impact of our guidance

    Our impact reports look at how the health and care system uses NICE's recommendations to improve people's health and care.

  3. What is the prognostic value of different risk stratification methods for people with locally advanced prostate cancer?

    advanced prostate cancer? Any explanatory notes(if applicable) Source guidance details Comes from guidance Prostate cancer:...

    Research recommendation
    Published
    25 October 2019

  4. Lower urinary tract symptoms in men (QS45)

    This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 September 2013
    View quality statements

    Sections for QS45

  5. Further research is recommended to determine the impact of MRI fusion biopsy systems compared with cognitive fusion biopsy on the detection of different grades of prostate cancer.

    with cognitive fusion biopsy on the detection of different grades of prostate cancer. Any explanatory notes(if applicable) Further...

    Research recommendation
    Published
    11 July 2023

  6. Clinicians should collect data on all patients undergoing focal cryoablation (including details of case selection, methods of follow-up and outcomes) for local audit. Clinicians should enter details about all patients undergoing focal therapy using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate (EuCAP) register and review clinical outcomes locally.

    using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate...

    Research recommendation
    Published
    9 June 2015

  7. MRI-guided laser interstitial thermal therapy for early prostate cancer

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  8. Laparoscopic radical prostatectomy (IPG193)

    Evidence-based recommendations on laparoscopic radical prostatectomy. This involves removing the prostate gland and some surrounding tissue using specialised instruments through small cuts in the abdomen (keyhole surgery).

    Interventional procedures guidance
    Published
    22 November 2006
    View recommendations

    Sections for IPG193

  9. What is the effectiveness and cost effectiveness of different scheduling of zoledronic acid in the prevention and reduction of skeletal events in people with hormone-refractory prostate cancer?

    hormone-refractory prostate cancer? Any explanatory notes(if applicable) Source guidance details Comes from guidance Prostate...

    Research recommendation
    Published
    25 October 2019

  10. NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.

    routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone,...

    Research recommendation
    Published
    9 June 2015

  11. NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies comparing the procedure against other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local recurrence in the long term.

    NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies...

    Research recommendation
    Published
    9 June 2015

  12. Cancers insufficiently researched in primary care: Observational studies of symptomatic primary care patients should be used to estimate the positive predictive value of different symptoms for specific cancers. Priority areas for research are those where the evidence base is currently insufficient and should include prostate cancer, pancreatic cancer, cancer in childhood and young people and other rare cancers. Outcomes of interest are positive predictive values and likelihood ratios for cancer.

    Recommendation ID NG131/03 Question Cancers insufficiently researched in primary care: Observational studies of symptomatic primary care

    Research recommendation
    Published
    7 January 2022

  13. Public board meeting agenda and papers: November 2020

    Agenda and papers of the NICE public board meeting on 18 November 2020

  14. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  15. Evidence on the safety of focal therapy using high-intensity focused ultrasound for localised prostate cancer is adequate, but evidence on its efficacy is limited. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    focal therapy using high-intensity focused ultrasound for localised prostate cancer is adequate, but evidence on its efficacy is...

    Research recommendation
    Published
    5 May 2023